Clinical Trial

Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC

Study acronym: BARBICAN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
International, randomised, open label, neo-adjuvant phase II trial in women with newly diagnosed, non-metastatic, high-risk (node positive and/or tumour size ≥ 2cm), triple negative breast cancer. The study aims to evaluate the effects of adding ipatasertib to chemotherapy and atezolizumab in patients with and without PI3CA/AKT1/PTEN genetic alterations.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-10; most recent amendment 2026-05-05.
Trial Details
NCT Number NCT05498896
Lead Sponsor Queen Mary University of London
Collaborators: Westdeutsche Studiengruppe GmbH (WSG), MedSIR, Hoffmann-La Roche
Conditions Triple Negative Breast Cancer
Enrollment 146 participants
Start Date 2018-12-19
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-08